Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 4, 2006, Pages 1106-1111

  Schild, Steven E ^a   McGinnis, William L ^b   Graham, David ^c   Hillman, Shauna ^a   Fitch, Tom R ^d   Northfelt, Donald ^d   Garces, Yolanda I ^a   Shahidi, Homayoon ^e   Tschetter, Loren K ^f   Schaefer, Paul L ^g   Adjei, Alex ^a   Jett, James ^a  

^a MAYO CLINIC   (United States)

^b Oncology Research Association CCOP   (United States)

^c Carle Cancer Center Community Clinical Oncology Program   (United States)

^d Scottsdale Comm Clin Oncol Prog   (United States)

^e MeritCare Hospital   (United States)

^f Sioux Community Cancer Consortium   (United States)

^g Toledo Community Hospital Oncology Program   (United States)

Author keywords

3D planning; Combined modality therapy; Concurrent chemotherapy; Dose escalation; Lung cancer; Phase 1 trial; Radiation therapy

Indexed keywords

CHEMOTHERAPY; DOSIMETRY; PATIENT MONITORING; PULMONARY DISEASES; TUMORS;

3D PLANNING; COMBINED MODALITY THERAPY; CONCURRENT CHEMOTHERAPY; DOSE ESCALATION; LUNG CANCER; PHASE 1 TRIAL;

RADIOTHERAPY;

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DERMATITIS; DYSPNEA; ESOPHAGITIS; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; SAFETY; TOXICITY; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 33745185115     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.02.046     Document Type: Article

References (26)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
3. Videtic G., Vokes E., Turrisi A., et al. (Abstract 2557). The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. (2003), ASCO, Chicago, Illinois The 39th annual meeting of the American Society of Clinical Oncology. p. 291
4. Perez C. Non-small cell carcinoma of the lung. Dose-time parameters. Cancer Treatment Symp 2 (1985) 131-142
5. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer. Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
6. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588. Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (1995) 198-205
7. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
8. Le Chevalier T., Arriagada R., Tarayre M., et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. [Letter]. J Natl Cancer Inst 84 (1992) 58
9. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
10. Komaki R., Seiferheld W., Curran W., et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC). Analysis of failures in a phase III study (RTOG 9410). [Abstract]. Int J Radiat Oncol Biol Phys 48 (2000) 113
11. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
12. Fletcher G.H., and Shukovsky L.J. The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 56 (1975) 383-400
13. Mehta M., Scrimger R., Mackie R., Paliwal B., Chappell R., and Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49 (2001) 23-33
14. Choy H., Safran H., Akerley W., et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4 (1998) 1931-1936
15. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311. A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
16. Bradley J.D., Graham M., Swann S., et al. Phase I Results of RTOG L-0117; a Phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC. [Abstract]. ASCO Annual Meeting Proceedings 23 (2005) 636s
17. Sim S., Rosenzweig K.E., Schindelheim R., et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 660-665
18. Rosenzweig K.E., Sim S.E., Mychalczak B., et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 681-685
19. Belderbos J.S., De Jaeger K., Heemsbergen W.D., et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 66 (2003) 119-126
20. Senan S., Burgers S., Samson M.J., et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 54 (2002) 999-1006
21. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy. Update of a phase I trial. J Clin Oncol 19 (2001) 127-136
22. Schild S.E., Korte S.M., Wong W.W., et al. Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Med Dosim 29 (2004) 196-203
23. Rosenzweig K.E., Amols H., and Ling C.C. New radiotherapy technologies. Semin Surg Oncol 21 (2003) 190-195
24. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
25. Blackstock A.W., Socinski M.A., and Gu L. Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC). A Cancer and Leukemia Group B (CALGB) randomized phase II trial. [Abstract]. ASCO Annual Meeting Proceedings 23 (2005) 635s
26. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer. A dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350